Pulmatrix (NASDAQ: PULM) Investor Presentation

October 8, 2018 admin Healthcare, Investor Presentations Comments Off on Pulmatrix (NASDAQ: PULM) Investor Presentation

Pulmatrix (NASDAQ: PULM) Investor Presentation 9/5/2018
Pulmatrix Corporate Overview (2018.08) – final for website

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.




Related Articles

Healthcare

CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

July 1, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of […]

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH

October 3, 2019 admin Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Clinical Trial of Leronlimab (PRO 140) for Treatment of NASH

VANCOUVER, Washington, Oct. 01, 2019– CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today FDA clearance […]